Table 2.

Safety through 30 days postvaccination with PCV-13

Event, n (%)	UPA 15 mg QD (N=87)	UPA 30 mg QD (N=24)
Any AE	15 (17.2)	3 (12.5)
AEs occurring in >1 patient
Fever	2 (2.3)	0
Nasopharyngitis	3 (3.4)	0
Onychomycosis	2 (2.3)	0
Upper respiratory tract infection	1 (1.1)	1 (4.2)
Serious AE	0	0
AE leading to discontinuation of study drug	0	0
AE with reasonable possibility of being related to UPA*	1 (1.1)	1 (4.2)
Death	0	0

*As assessed by the investigator.

AE, adverse event; PCV-13, pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein); QD, once daily; UPA, upadacitinib.